Shanghai Fosun Pharmaceutical's (SHA:600196, HKG:2196) subsidiary, Suzhou Junming, agreed to the addition of a new investor in its biologics-focused private equity fund, Hangzhou Fund, and waived its right to receive shares transferred from another investor, according to a Shanghai bourse filing Thursday.

Porton Pharma Solutions acquired the 3.75% stake in the fund, which is worth 30 million yuan, from Ningbo Xinhui.

After the transaction, Ningbo Xinhui's share in the fund was reduced to 3.13% from 6.88%.

The pharmaceutical company's Shanghai and Hong Kong shares both rose 1% during the morning trade.